HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Shenzhen Mindray Bio-Medical Electronics (300760.CH) - Some Points Worth the Attention

United Laboratories International Holdings Placement (3933.HK) - Valuation Pullback Seems Inevitable

BeiGene (6160.HK/BGNE.US) - The Truth Behind Novartis' Divorce Decision on PD-1

Shenzhen Mindray Bio-Medical Electronics (300760.CH) 2022H1 - Waiting for the Next Jump in Valuation

2023 High Conviction Update: Sonoscape Medical (300633.CH) - High Growth Is Expected to Continue

Shenzhen Mindray Bio-Medical Electronics (300760.CH) - Shareholders' Stock Selling and the Outlook

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Equity Bottom-Up

Shenzhen Mindray Bio-Medical Electronics / Equity Bottom-Up

Shenzhen Mindray Bio-Medical Electronics (300760 CH)

<ul>
<li>There's an obvious declining trend in net profit YoY growth.Considering unsatisfactory growth of MI and IVD in 22H2,if it weren't for the strong growth of PMLS,Mindray's overall growth could have been "surprising".</li>
<li>The current question is whether IVD and MI segments would have high enough growth to offset the potential performance decline of PMLS segment in post-pandemic era. Problems may emerge afterwards.</li>
<li>There are still some unresolved technical challenges that constrain the development of Mindray. Without good performance in internationalization, there is no incremental market. Thus no reason to maintain high valuation.</li>
</ul>


There's an obvious declining trend in net profit YoY growth.Considering unsatisfactory growth of MI and IVD in 22H2,if it weren't for the strong growth of PMLS,Mindray's overall growth could have been "surprising".
The current question is whether IVD and MI segments would have high enough growth to offset the potential performance decline of PMLS segment in post-pandemic era. Problems may emerge afterwards.
There are still some unresolved technical challenges that constrain the development of Mindray. Without good performance in internationalization, there is no incremental market. Thus no reason to maintain high valuation.


Shenzhen Mindray Bio-Medical Electronics (300760.CH) - This Year's Challenge Is Not over Yet